Pinnacle Clinical Research, a portfolio company of LongueVue Capital, announced on January 10 its successful combination with South Texas Research Institute (STRI).
The combined Pinnacle and STRI platform expands its network and geographic footprint to six stand-alone and dedicated sites, enhances patient recruitment diversity and increases scale. STRI’s Founder and CEO Dr. Rashmee Patil will assume the role of CEO of the combined business. Terms of the deal were not disclosed.
Headquartered in Edinburg, Texas, South Texas Research Institute is a multi-location clinical site organization specializing in complex indications, including hepatology with a focus on non-alcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH). The company operates two of the leading NASH enrollment sites in the country and has a reputation for superior patient recruitment and care focused on a diverse patient population in the Rio Grande Valley.
Pinnacle Clinical Research is dedicated to conducting clinical trials in the areas of hepatology and gastroenterology, with a special focus on fatty liver disease.
According to data captured in the LevinPro HC database, this marks the first deal in the clinical trials subsector of 2023. There were 28 clinical trials transactions announced in 2022.
